NASDAQ:PNT POINT Biopharma Global (PNT) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free PNT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$12.49▼$12.5150-Day Range$12.45▼$14.2352-Week Range$6.57▼$14.35Volume3.29 million shsAverage Volume1.44 million shsMarket Capitalization$1.33 billionP/E Ratio13.89Dividend YieldN/APrice Target$12.80 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get POINT Biopharma Global alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About POINT Biopharma Global Stock (NASDAQ:PNT)POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. PNT Stock News HeadlinesApril 8, 2024 | bloomberg.comInvesting in biopharma innovation: Can you stay one step ahead?January 8, 2024 | businesswire.comDomain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology CompanyApril 23, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.December 27, 2023 | finance.yahoo.comLilly Completes Acquisition of POINT BiopharmaDecember 22, 2023 | markets.businessinsider.comPOINT Biopharma Global Rating Adjustment: Hold Recommendation Following Shareholder Dynamics and Acquisition ProspectsDecember 22, 2023 | msn.comBrookline Capital Downgrades POINT Biopharma Global (PNT)December 22, 2023 | benzinga.comPOINT Biopharma Global Stock (NASDAQ:PNT), Guidance and ForecastDecember 18, 2023 | msn.comLilly extends tender offer for POINT Biopharma to Dec. 22April 23, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.December 18, 2023 | seekingalpha.comWhy POINT Biopharma Global Is At Least A Hold On Disappointing ReadoutDecember 18, 2023 | markets.businessinsider.comLantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study ResultsDecember 8, 2023 | msn.comPOINT Biopharma Global Inc. (PNT) Upgraded to Buy: Here's What You Should KnowDecember 4, 2023 | markets.businessinsider.comLilly Says Tender Offer Expiration Extended Related To POINT Biopharma AcquisitionNovember 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)November 17, 2023 | markets.businessinsider.comHold Rating on POINT Biopharma Global: An Assessment of Acquisition Offer, Pipeline Updates, and Financial StabilityNovember 17, 2023 | finance.yahoo.comLilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023November 15, 2023 | benzinga.comPOINT Biopharma Global Stock (NASDAQ:PNT) Earnings Dates and Earning CallsNovember 15, 2023 | markets.businessinsider.comLilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT BiopharmaNovember 15, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Hold Rating on POINT Biopharma Global (PNT)November 14, 2023 | benzinga.comPOINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price?November 14, 2023 | seekingalpha.comPOINT Biopharma Global: Why The Market Believes That A Second Bidder May EmergeNovember 13, 2023 | benzinga.comRecap: POINT Biopharma Global Q3 EarningsNovember 13, 2023 | markets.businessinsider.comPOINT Biopharma Reports Loss In Q3, Flat With Last Year, A Week After Lilly Agreed To Acquire ItNovember 13, 2023 | finance.yahoo.comPOINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNovember 8, 2023 | msn.comEli Lilly extends expiration of tender offer to acquire Point BiopharmaNovember 8, 2023 | markets.businessinsider.comLilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16November 8, 2023 | finance.yahoo.comLilly Announces Extension of Tender Offer to Acquire POINT BiopharmaSee More Headlines Receive PNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for POINT Biopharma Global and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PNT CUSIPN/A CIK1811764 Webwww.pointbiopharma.com Phone64-7812-2417FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Target$12.80 High Stock Price Target$14.00 Low Stock Price Target$12.50 Potential Upside/Downside+2.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.90 Trailing P/E Ratio13.89 Forward P/E RatioN/A P/E GrowthN/ANet Income$98.29 million Net Margins39.62% Pretax Margin52.16% Return on Equity21.10% Return on Assets18.28% Debt Debt-to-Equity Ratio0.01 Current Ratio9.14 Quick Ratio9.14 Sales & Book Value Annual Sales$226.58 million Price / Sales5.88 Cash Flow$0.94 per share Price / Cash Flow13.31 Book Value$4.68 per share Price / Book2.67Miscellaneous Outstanding Shares106,570,000Free Float89,518,000Market Cap$1.33 billion OptionableOptionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Allan Charles Silber (Age 73)Executive Chairman Comp: $1.02MDr. Joe A. McCann Ph.D. (Age 45)CEO & Director Comp: $1.06MDr. Neil E. Fleshner FRCSC (Age 59)M.D., M.PH, Chief Medical Officer & Director Comp: $318.49kMs. Jessica D. Jensen M.P.H. (Age 43)Executive Vice President of Clinical Development Comp: $816.17kMr. Bill Demers B.B.A. (Age 64)F.C.A., FCPA, CFO & Corporate Secretary Comp: $78.26kMs. Justyna Kelly M.Sc. (Age 38)Chief Operating Officer Ms. Jazz BraichSVP of People & CultureMr. Ari ShomairVP of Corporate Affairs & Chief of StaffDr. Myra Rosario Herle Ph.D.R.Ph., Executive Vice President of Regulatory AffairsDr. Matthew P. Vincent J.D.Ph.D., Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsVerona PharmaNASDAQ:VRNAGyre TherapeuticsNASDAQ:GYREANI PharmaceuticalsNASDAQ:ANIPDay One BiopharmaceuticalsNASDAQ:DAWNMorphicNASDAQ:MORFView All CompetitorsInstitutional OwnershipPerceptive Advisors LLCSold 800,000 shares on 2/26/2024Ownership: 0.000%View All Institutional Transactions PNT Stock Analysis - Frequently Asked Questions Should I buy or sell POINT Biopharma Global stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for POINT Biopharma Global in the last twelve months. There are currently 10 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PNT, but not buy additional shares or sell existing shares. View PNT analyst ratings or view top-rated stocks. What is POINT Biopharma Global's stock price target for 2024? 10 brokerages have issued 1 year price targets for POINT Biopharma Global's stock. Their PNT share price targets range from $12.50 to $14.00. On average, they anticipate the company's stock price to reach $12.80 in the next year. This suggests a possible upside of 2.4% from the stock's current price. View analysts price targets for PNT or view top-rated stocks among Wall Street analysts. How were POINT Biopharma Global's earnings last quarter? POINT Biopharma Global Inc. (NASDAQ:PNT) posted its quarterly earnings results on Monday, November, 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.07. The firm earned $2.79 million during the quarter, compared to the consensus estimate of $8 million. POINT Biopharma Global had a net margin of 39.62% and a trailing twelve-month return on equity of 21.10%. This page (NASDAQ:PNT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding POINT Biopharma Global Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
